GlassScriptPhysician profile
Chris A Sparkman
NPI 1073618104
$4,796.31
in general payments reported to CMS, 2019-2025
43 companies · $844 in 2025
The $844 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $898 · 2020: $354 · 2021: $552 · 2022: $694 · 2023: $690 · 2024: $764 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,298.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.42 | 2021-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $665.84 | 2019-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $262.22 | 2022-2025 | |
| Lilly USA, LLC | $251.56 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $238.53 | 2019-2025 | Airsupra |
| Esperion Therapeutics, INC. | $213.74 | 2020-2025 | Nexletol |
| Abbott Laboratories | $166.30 | 2019-2025 | Proclaim, Eterna, Freestyle Libre 3 |
| Novo Nordisk INC | $165.63 | 2019-2025 | Wegovy |
| Biotronik INC. | $141.10 | 2019 | |
| Sanofi-Aventis U.S. LLC | $122.07 | 2019-2022 | |
| Allergan, INC. | $119.18 | 2019-2020 | |
| Antares Pharma, INC. | $113.05 | 2019-2025 | Xyosted |
| Pfizer INC. | $106.12 | 2019-2025 | |
| Soleno Therapeutics, INC. | $104.87 | 2025 | Vykat Xr |
| Idorsia Pharmaceuticals US INC | $104.47 | 2022-2024 | Quviviq |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Sparkman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.